|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM35472097X |
| 003 |
DE-627 |
| 005 |
20231226062826.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109298
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1182.xml
|
| 035 |
|
|
|a (DE-627)NLM35472097X
|
| 035 |
|
|
|a (NLM)36967024
|
| 035 |
|
|
|a (PII)S1521-6616(23)00077-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Zhimian
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Baricitinib for the treatment of refractory vascular Behçet's disease
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.04.2023
|
| 500 |
|
|
|a Date Revised 07.05.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a OBJECTIVE: The pilot study aims to evaluate the effectiveness and safety of baricitinib in Behcet's Disease (BD) patients with refractory vascular involvement
|
| 520 |
|
|
|a METHODS: We consecutively enrolled vascular/cardiac BD patients who received baricitinib (2 mg/day) along with glucocorticoids (GCs) and immunosuppressants in our center. Efficacy assessment mainly depends on the proportion of clinical remission and side effects were recorded
|
| 520 |
|
|
|a RESULTS: 17 patients (12 males) were included with a mean follow-up of 10.7 ± 5.3 months. At 3 months of follow-up, 76.5% of patients achieved a complete response and the proportion increased to 88.2% at the last visit. During follow-up, ESR (p < 0.01) and hsCRP (p < 0.0001) decreased significantly, as well as Behçet's Disease Current Activity Form score (p < 0.01). In addition, baricitinib showed a GCs-sparing effect. No serious adverse events were noted
|
| 520 |
|
|
|a CONCLUSIONS: Our study suggests that baricitinib is well-tolerated and effective in treating refractory vascular/cardiac BD patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Baricitinib
|
| 650 |
|
4 |
|a Behçet's disease
|
| 650 |
|
4 |
|a Biologics therapy
|
| 650 |
|
4 |
|a Refractory
|
| 650 |
|
4 |
|a Vascular/cardiac involvement
|
| 650 |
|
7 |
|a baricitinib
|2 NLM
|
| 650 |
|
7 |
|a ISP4442I3Y
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Sulfonamides
|2 NLM
|
| 650 |
|
7 |
|a Glucocorticoids
|2 NLM
|
| 700 |
1 |
|
|a Wang, Xiaoou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Weiwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yuhua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Jinjing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Shangzhu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tian, Xinping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Yan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Wenjie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 250(2023) vom: 24. Mai, Seite 109298
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:250
|g year:2023
|g day:24
|g month:05
|g pages:109298
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109298
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 250
|j 2023
|b 24
|c 05
|h 109298
|